A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1441 participants.
Also called NCT04017832
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,441 participants
- Sponsor
- Registry
-
NCT04017832 -
2018-002589-38
-
- Other papers using this trial's data
- Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Algeria, Brazil, China, Czechia, Hong Kong SAR China, Romania, Serbia, South Africa, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT04017832. Randomized; quadruple masking; primary purpose treatment. Start 2019-07-29 (actual); primary completion 2021-10-27 (actual). Results posted on 2023-09-29.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes
- Acronym
- PIONEER 12
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Oral semaglutide
- Intervention (Drug)
- Sitagliptin
- Intervention (Drug)
- Placebo (oral semaglutide)
- Intervention (Drug)
- Placebo (sitagliptin)
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct04017832- Content hash
f7b33b715aac77d43ccbcef81d626e42c0ef42a4d4d2c6c35547ae1f828a4df5